Vertex Pharmaceuticals Inc / Ma (VRTX) Files Form 4 Insider Selling : Joshua S Boger Sells 5,130 Shares

Vertex Pharmaceuticals Inc / Ma (VRTX): Joshua S Boger , director of Vertex Pharmaceuticals Inc / Ma sold 5,130 shares on May 11, 2016. The Insider selling transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were sold at $86.31 per share for a total value of $443,739.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Paul M Silva (SVP & Corp Controller) sold 3,000 shares at $87.54 per share price.On May 6, 2016, Joshua S Boger (director) sold 5,130 shares at $81.35 per share price.Also, On Feb 4, 2016, Ian F Smith (EVP & CFO) sold 12,084 shares at $91.32 per share price.On Feb 4, 2016, Amit Sachdev (EVP, Policy, Access & Value) sold 10,166 shares at $91.38 per share price.

Vertex Pharmaceuticals Incorporated: On Tuesday, May 10, 2016 heightened volatility was witnessed in Vertex Pharmaceuticals Incorporated which led to swings in the share price. The shares opened for trading at $88.58 and hit $89.1 on the upside , eventually ending the session at $89.08, with a gain of 1.16% or 1.02 points. The heightened volatility saw the trading volume jump to 20,95,059 shares. The 52-week high of the share price is $143.45 and the company has a market cap of $22,034 M . The 52-week low of the share price is at $75.9.

Vertex Pharmaceuticals Incorporated Money Flow Index Chart

Company has been under the radar of several Street Analysts.Vertex Pharmaceuticals Incorporated is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 115 from a previous price target of $135 . The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Barclays to Overweight while Lowering the Price Target of the company shares to $ 110 from a previous price target of $135 . The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Downgraded by Goldman to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 28, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 108 from a previous price target of $140 . The Rating was issued on Apr 1, 2016.Vertex Pharmaceuticals Incorporated is Reiterated by RBC Capital Mkts to Outperform while Lowering the Price Target of the company shares to $ 135 from a previous price target of $145 . The Rating was issued on Mar 18, 2016.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Leave a Reply

Vertex Pharmaceuticals Incorporated - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vertex Pharmaceuticals Incorporated. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.